AUTHORS
Bradley Hunter, MD, MPH, Megan Mullalley, PharmD, BCOP2, Melissa Banner, MBA, MSN, RN3, Jacob Wilkes, BS4, Tom Belnap, MS5, David M Gill, MD6, Andrew J Knighton, PhD MS7
AFFILIATIONS
1 Intermountain Health, Salt Lake City, Utah, United States
2 Intermountain Health, Murray, Utah, United States
3 Intermountain Health, Murray, Utah, United States
4 Intermountain Health, Salt Lake City, United States
5 Intermountain Health, Salt Lake City, Utah, United States
6 Intermountain Health, Murray, Utah, United States
7 Independent Senior Scientist, Implementation and Evaluation Research, Farmington, Utah, United States
ABSTRACT
Introduction
Bispecific antibodies (BsAbs) are used as later-line therapy for patients who relapse or become refractory to standard treatments across hematologic cancers [B-cell lymphoma (lymphoma), multiple myeloma (MM)] and select solid tumors [small cell lung cancer (SCLC), uveal melanoma (UM)]. Unlike chimeric antigen receptor T-cell (CAR-T) therapy, which requires personalized manufacturing and specialized treatment centers, BsAbs can start quickly, suit older and frailer patients, and be delivered in local outpatient settings, improving access for rural populations. Their rapid adoption highlights the need for real-world evidence on community integration, especially in rural settings.
Methods
Retrospective real world data study describing expansion of 10 BsAbs—lymphoma: blinatumomab, epcoritamab, glofitamab, mosunetuzumab; MM: elranatamab, talquetamab, teclistamab; SCLC: amivantamab, tarlatamab; UM: tebentafusp—across 10 Intermountain Health community hospital sites (nine serving rural areas) and a tertiary Cell Therapy Services center in Salt Lake City, Utah. Eligible patients received ≥1 BsAb dose from Jan 1, 2020–Jun 30, 2026. In 2024, six sites were trained to deliver step-up and maintenance dosing of BsAbs, with emergency room/intensive care unit (ICU) teams educated on managing cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANs), supported by Center experts.
Results
During the study period, 179 patients [lymphoma 73; MM 57; SCLC 45; UM 4] received 2,381 doses [lymphoma 901; MM 988; SCLC 417; UM 75]. Utilization increased from 2 new patients in 2020 to 42 new patients in the first half of 2026. 54% of the patient population was male with median age 63 [lymphoma 62; MM 72; SCLC 67; UM 66]. 97% of patients were White with 7% Hispanic ethnicity and 67% married/partnered. Patients resided in 7 states with 15% in rural areas and 14% in high deprivation neighborhoods. 87% of patients had at least one comorbidity (excluding index cancer).
For lymphoma, blinatumomab (26%) was the most common start drug used over the study period though by 2026 glofitamab (42%) and epcoritamab (33%) were more common. For MM, teclistamab and talquetamab had similar usage (~40-45% each) over the study period, remaining the most common in 2026. For SCLC, amivantamab (62%) was the most common start drug used over the study period. By the first half of 2026, amivantamab and tarlatamab were equally prescribed.
Between 2020-2023, 12% of new patients (6% doses) received BsAbs treatment outside a central expert center. In 2026, 40% of new patients (42% doses) received treatment in a local hospital. Median round trip travel distance across all patients improved by 50% from 55 miles in 2020-2023 to 28 miles in 2024-2026. For rural patients, travel distance per round trip decreased from 269 to 133 miles. Distance coming from high deprivation neighborhoods fell 84% from a median of 195 to 32 miles per round trip. Given increased local access, 81 patients (45%) had a shorter round-trip distance for the 3-4 initial dosing visits reducing their driving by a collective 120,000-150,000 miles. In addition to savings on fuel costs [average: $194-243 per patient], patients benefited from lower lodging and meal costs and reclaimed time.
11.7% of patients experienced any grade CRS within 60d of treatment start [Center: 13.1%; local hospitals: 10.0%] and varied by cancer type [lymphoma 12.3%; MM 15.8%; SCLC 4.4%; UM 25.0%]. 2.2% of patients experienced ICANS (all grade level 1) within 60 days of treatment start [Center: 1.6%; local hospitals: 3.6%] and varied by cancer type [lymphoma 2.7%; MM 0.0%; SCLC 4.4%; UM 0.0%]
Patient 60d ICU admission rates were 6.7% [Center: 10.1%; local hospitals: 2.5%] and varied by cancer type [lymphoma 9.6%; MM 3.5%; SCLC 6.7%; UM 0%]. No patient treated in a local hospital required transfer to the Center ICU. 30d, 60d and 90d mortality rates were 3.9%, 8.4% and 10.1% respectively [30d: Center 4.0%, local hospitals 3.6%; 60d: Center 8.9%, local hospitals 7.3%; 90d: Center 10.5%, local hospitals 9.1%].
Conclusion
Implementation of a BsAbs access expansion program in a community-based health system demonstrated feasibility in transitioning care to local hospitals, reducing patient burden, and improving access to advanced cancer care. Greater benefits are seen for patients from rural communities. There were no observed differences in safety outcomes, including mortality.
DISCLOSURES
Bradley Hunter, MD, MPH: Caribou Biosciences - Honoraria; Poseida Therapeutics - Honoraria; Kite - Honoraria; BMS - Honoraria; Kyverna (paid to institution) - Honoraria; Johnson & Johnson - Honoraria; Novartis - Honoraria; Johnson & Johnson - Research Funding; BMS - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Kyverna - Consultancy (Includes expert testimony); Caribou Biosciences - Consultancy (Includes expert testimony); Poseida Therapeutics - Consultancy (Includes expert testimony)